Author

Laura Stanbery

Research Fellow, University of Michigan - Cited by 679 - Cancer Biology

Biography

Laura Stanbery is currently working as a Professor in the Department of Medicine. His research interests includes Medicine. Laura Stanbery is serving as an editorial member and reviewer of several international reputed journals. Laura Stanbery has successfully completed his Administrative responsibilities. Laura Stanbery  has authored of many research articles/books related to Medicine
Title
Cited by
Year
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
K Choucair, S Morand, L Stanbery, G Edelman, L Dworkin, J NemunaitisCancer gene therapy 27 (12), 841-853, 2020202
89
2020
Ovarian cancer immunotherapy and personalized medicine
S Morand, M Devanaboyina, H Staats, L Stanbery, J NemunaitisInternational Journal of Molecular Sciences 22 (12), 6532, 2021202
83
2021
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
RP Rocconi, EA Grosen, SA Ghamande, JK Chan, MA Barve, J Oh, ...The lancet oncology 21 (12), 1661-1672, 2020202
68
2020
The abscopal effect of radiation therapy
DJ Craig, NS Nanavaty, M Devanaboyina, L Stanbery, D Hamouda, ...Future Oncology 17 (13), 1683-1694, 2021202
54
2021
Current ovarian cancer maintenance strategies and promising new developments
V Gogineni, S Morand, H Staats, R Royfman, M Devanaboyina, K Einloth, ...Journal of Cancer 12 (1), 38, 2021202
33
2021
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies
O Willis, K Choucair, A Alloghbi, L Stanbery, R Mowat, ...Cancer gene therapy 27 (9), 634-644, 2020202
24
2020
Homologous recombination proficiency in ovarian and breast cancer patients
JF Creeden, NS Nanavaty, KR Einloth, CE Gillman, L Stanbery, ...BMC cancer (1), 1-12, 202
21
2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
RP Rocconi, BJ Monk, A Walter, TJ Herzog, E Galanis, L Manning, ...Gynecologic oncology 161 (3), 676-680, 212
20
2021
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
J Oh, M Barve, N Senzer, P Aaron, L Manning, G Wallraven, E Bognar, ...Gynecologic Oncology Reports 34, 2020202
18
2020
FDA efficiency for approval process of COVID-19 therapeutics
C Cassidy, D Dever, L Stanbery, G Edelman, L Dworkin, J NemunaitisInfectious Agents and Cancer 15 (1), 1-13, 2020202
18
2020
Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment
S Morand, H Staats, JF Creeden, A Iqbal, B Kahaleh, L Stanbery, ...Future Oncology 16 (9), 483-495, 2020202
18
2020
Resident memory T cells and their effect on cancer
DJ Craig, JF Creeden, KR Einloth, CE Gillman, L Stanbery, D Hamouda, ...Vaccines 8 (4), 562, 2020202
17
2020
BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
S Morand, L Stanbery, A Walter, RP Rocconi, J NemunaitisJNCI Cancer Spectrum 4 (6), pkaa077, 2020202
14
2020
Vigil: personalized immunotherapy generating systemic cytotoxic T cell response
J Herron, N Smith, L Stanbery, P Aaron, L Manning, E Bognar, ...Cancer Sci. Res 3 (1), 1-4, 2020202
14
2020
Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology
N Ngo, K Choucair, JF Creeden, H Qaqish, K Bhavsar, C Murphy, K Lian, ...Future Oncology 15 (33), 3861-3876, 2019201
13
2019
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
J Nemunaitis, L Stanbery, N SenzerFuture Virology 15 (6), 381-395, 2020202
12
2020
HER2-positive metastatic cervical cancer responsive to first and second-line treatment: a case report
D Fortman, R Issa, L Stanbery, M Albrethsen, J Nemunaitis, T KasunicGynecologic Oncology Reports 31, 100520, 2020202
12
2020
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer
R Royfman, E Whiteley, O Noe, S Morand, J Creeden, L Stanbery, ...Future Oncology 17 (21), 2817-2830, 2021202
11
2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer
A Walter, RP Rocconi, BJ Monk, TJ Herzog, L Manning, E Bognar, ...Gynecologic Oncology 163 (3), 45-464, 2021202
9
2021
Long-term follow-up of gemogenovatucel-T (Vigil) survival and molecular signals of immune response in recurrent ovarian cancer
RP Rocconi, L Stanbery, L Madeira da Silva, RA Barrington, P Aaron, ...Vaccines (8), 84, 2021202
9
2021

Referred From: https://scholar.google.com/citations?hl=en&user=LnSevsAAAAAJ

Cited by
Citations 679
h-index 14
i10-index 20
Recommended Journals
Open Access Journals